EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

BillionToOne, Inc. Class A Common Stock (BLLN) fair value: what the stock is really worth

We calculate from audited financials what BillionToOne, Inc. Class A Common Stock is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US0901681058

BI BillionToOne, Inc. Class A Common Stock logo Thin data Sep 13, 2026

BillionToOne, Inc. Class A Common Stock

BLLN · US

Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $16.67 · Strongly overvalued (−83%)
Quality 68/100
Healthy Growth (revenue YoY +100.0 %/yr)
!Thin margins · 7.0% net margin (TTM)
Low debt · generates free cash flow
!Mixed vs. peers (6/12)
!Moderate moat 48/100
!Evidence only low, so the estimate is less certain
Watch BillionToOne, Inc. Class A Common Stock for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$149.97 $64.03 Fair Value $16.67 Nov 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year. As of Sep 13, 2026.

How to read this chart

10‑month range $64.03 – $149.97 · fair‑value band $14.62 – $19.32 · the $98.77 price screens above the $16.67 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.

Show more

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

Stock analysis

BillionToOne, Inc. Class A Common Stock (BLLN) currently trades at $98.77, while our model-based Fair Value estimate is $16.67, implying the stock looks roughly 492.4% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $19.69 per share, and 0 of the 24 models we run sit above the $98.77 price.

Bear case: the Multiples group reads lowest at $3.96, and 24 of the 24 models stay below the price. Evidence for this calculation is low.

Scenario range: $14.62 (bear) to $19.32 (bull), the price of $98.77 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

BillionToOne, Inc. Class A Common Stock reported revenue of $305M in FY2025 versus $71.7M in FY2023, a compound +106.2%/yr. Reported net income was $7.5M in FY2025.

Key figures

Market cap $6.0B · P/E ratio 182.1 · P/S ratio 4.45 · EPS (TTM) $0.5400 · Net margin 2.4% · Return on equity 8.7% · Return on assets (EBIT) −16.4% · Operating margin 16.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 29% below its 52-week high and 59% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 1% fair-value upside, at −83%, BLLN screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely ($3.06 to $26.07). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear $14.62 Fair Value $16.67 Bull $19.32
Model Each model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then ($0.3802 per share) are deliberately not added. Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence Evidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV $13.75 $14.25 $14.68 74
FCF DCF $16.62 $19.87 $30.02 72
Growth DCF $16.25 $21.37 $29.61 71
All 24 models by family
DCF Models
FCF DCF $16.62 $19.87 $30.02 72
Owner Earnings $14.34 $18.91 $28.14 68
5Y Revenue Exit $15.09 $18.24 $24.82 66
5Y EBITDA Exit $17.54 $23.18 $34.26 67
5Y P/E Exit $14.50 $18.57 $23.98 64
10Y Revenue Exit $15.47 $20.94 $24.31 61
10Y EBITDA Exit $17.36 $26.07 $41.39 60
10Y P/E Exit $15.20 $19.69 $26.77 58
Earnings-Based
Graham-Dodd $1.22 $8.53 $11.97 56
Lynch FV $4.41 $6.30 $8.18 54
PEG = 1.0 $4.41 $6.30 $8.18 51
EPV $13.75 $14.25 $14.68 74
Multiples
P/E Multiple $2.97 $3.96 $4.95 63
P/S Multiple $2.29 $3.06 $3.82 58
P/B Multiple $2.29 $3.06 $3.82 55
EV/EBIT $15.52 $17.16 $18.80 66
EV/EBITDA $17.66 $20.02 $22.38 67
EV/Revenue $14.11 $15.61 $17.12 54
Asset-Based
NCAV (Graham) $5.79 $7.76 $11.58 54
Growth DCF
Growth DCF $16.25 $21.37 $29.61 71
Rev-Margin DCF $15.55 $19.35 $27.29 65
Economic Profit
Residual Income $7.91 $7.38 $5.50 63
ROIC Compounder $14.73 $16.89 $19.71 64
Growth Earnings
Growth-Adj P/E $5.85 $8.36 $10.86 60

Open the full fair value analysis →

Notify me when BLLN reaches fair value

Put BLLN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 68/100

Of which business quality 66 · Market factors (momentum, volatility) 42

Profitability 31
Margins and returns on capital today
Quality Growth 88
Are margins and returns improving?
Cashflow 55
Earnings quality: real cash, not paper profit
Fin. Strength 88
Balance sheet, leverage, solvency risk
Investment 95
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 75
Price trend over the last 3–12 months (market factor)
52W Momentum 36
Distance to the 52-week high (market factor)
Net Issuance 56
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality Growth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
What shareholders gained per year We only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed

Growth Forecast

A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes This turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+62.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect Analysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+27.2%
Yearly sales growth analysts expect, extended to five years.
Forecast 2026 (sales)+48.8%
Forecast 2027 (sales)+27.1%
Projected 2028 (sales)+23.9%
Projected 2029 (sales)+20.8%
Projected 2030 (sales)+17.7%

BLLN screens 492% overvalued. Compare with Thermo Fisher Scientific Inc →

Earlier news

News mood News mood, the average tone of recent news (69 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Compare BillionToOne, Inc. Class A Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 140 stocks

Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 68 · Top 25%
Fair Value upside −91% · Bottom 25%
Profitability
Return on equity (TTM) 9% · Above median
Return on assets 4% · Above median
Net margin (TTM) 7% · Above median
Operating margin (TTM) 16% · Above median
Growth and dividend
Revenue growth 84% · Top 25%
Balance sheet
Debt / equity 0.12× · Above median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (TTM) 182.1× · Priciest 25%
P/B 12.48× · Priciest 25%
P/S (TTM) 16.91× · Priciest 25%
P/FCF 381.4× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 27
PAST (return on equity)35 · sector 9
HEALTH (low debt)94 · sector 96
DIVIDEND (yield)0 · sector 29

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $609.82 $616.38 +1%
Danaher Corporation DHR $200.14 $207.76 +4%
WuXi AppTec Co 2359 HK$188.80 HK$213.30 +13%
Lonza Group LONN CHF 531.20 CHF 151.69 −71%
IDEXX Laboratories, Inc IDXX $504.70 $511.54 +1%
Agilent Technologies, Inc A $146.93 $61.53 −58%
Waters Corporation WAT $408.34 $103.09 −75%
IQVIA Holdings IQV $261.77 $264.34 +1%
Illumina, Inc ILMN $206.45 $227.10 +10%
Mettler-Toledo International Inc MTD $1,294 $615.78 −52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "BillionToOne, Inc. Class A Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/BLLN

Frequently asked questions

Is BillionToOne, Inc. Class A Common Stock (BLLN) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $16.67 versus a price of $98.77, about −83% upside (overvalued).
What is the fair value of BLLN?
Our model-based fair value for BillionToOne, Inc. Class A Common Stock is $16.67 (as of Sep 13, 2026), built from audited fundamentals. The current price: $98.77.
What is the quality score of BLLN?
BillionToOne, Inc. Class A Common Stock has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BillionToOne, Inc. Class A Common Stock (BLLN)?
Our model-based price target is the fair value of $16.67 (as of Sep 13, 2026) from 24 valuation models. Cautious scenario $14.62, optimistic scenario $19.32. It is a calculation from audited fundamentals, not an analyst target.
What is the BillionToOne, Inc. Class A Common Stock stock forecast for 2026?
Our models put fair value at $16.67, about −83% upside versus a price of $98.77 (overvalued). Cautious scenario $14.62, optimistic scenario $19.32. The calculation is refreshed regularly with new filings.
What is the revenue of BillionToOne, Inc. Class A Common Stock (BLLN)?
BillionToOne, Inc. Class A Common Stock reported trailing-twelve-month revenue of about $355M (latest available figure, as of Sep 13, 2026).
What growth is priced into BillionToOne, Inc. Class A Common Stock (BLLN)?
For today's price to be fair in a discounted-cash-flow model, BillionToOne, Inc. Class A Common Stock would have to grow free cash flow by +62.2 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 2 years revenue grew +106.2 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of BLLN use?
Our models discount BillionToOne, Inc. Class A Common Stock at 9.7 %: a base by market capitalisation (mid), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BillionToOne, Inc. Class A Common Stock that is +62.2 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has BillionToOne, Inc. Class A Common Stock (BLLN) delivered so far?
Over the past 2 years revenue at BillionToOne, Inc. Class A Common Stock grew +106.2 % a year. The price currently implies +62.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BillionToOne, Inc. Class A Common Stock (BLLN) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into BillionToOne, Inc. Class A Common Stock (+62.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BillionToOne, Inc. Class A Common Stock (BLLN)?
The free-cash-flow yield on the price is 0.35 %: that much free cash flow BillionToOne, Inc. Class A Common Stock produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BillionToOne, Inc. Class A Common Stock (BLLN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BillionToOne, Inc. Class A Common Stock it is $16.67 per share (as of Sep 13, 2026), against a price of $98.77. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is BillionToOne, Inc. Class A Common Stock stock overvalued or undervalued in 2026?
As of Sep 13, 2026, BLLN trades above its calculated fair value: price $98.77, fair value $16.67, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BLLN?
No. The price is what the market pays today ($98.77); the fair value is what the company's own numbers justify ($16.67). For BillionToOne, Inc. Class A Common Stock the two are $82.10 per share apart. That gap is exactly why we show both numbers side by side.
How much is BillionToOne, Inc. Class A Common Stock worth?
The market values BillionToOne, Inc. Class A Common Stock at about $6.0B (market capitalisation, as of Sep 13, 2026). Per share that is $98.77; our models calculate a fair value of $16.67 per share.
What do the bullish and bearish scenarios say about BLLN?
Our models span a range for BillionToOne, Inc. Class A Common Stock: cautious scenario $14.62, base $16.67, optimistic $19.32 per share (as of Sep 13, 2026, price $98.77). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BLLN?
BillionToOne, Inc. Class A Common Stock trades at a price-to-earnings ratio of 182.1 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $16.67 is built from several models across several years. Other multiples: P/B 12.5, P/S 16.9.
How solid is the balance sheet of BillionToOne, Inc. Class A Common Stock (BLLN)?
Balance-sheet figures for BillionToOne, Inc. Class A Common Stock (as of Sep 13, 2026): return on equity 8.7%, debt of 0.12 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is BLLN from its 52-week high?
BillionToOne, Inc. Class A Common Stock trades at $98.77, about 29% below its 52-week high of $138.70 and 59% above the low of $61.96 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of $16.67 is for.
Which stocks are comparable to BillionToOne, Inc. Class A Common Stock?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BillionToOne, Inc. Class A Common Stock stock attractive at the current price?
The data as of Sep 13, 2026: price $98.77, calculated fair value $16.67 (−83%), Quality Score 68/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BLLN calculated?
We run BillionToOne, Inc. Class A Common Stock through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $16.67, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. BillionToOne, Inc. Class A Common Stock itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with BillionToOne, Inc. Class A Common Stock right now?
The price sits above even our optimistic bull case ($19.32). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of BillionToOne, Inc. Class A Common Stock

How large is the market capitalisation of BillionToOne, Inc. Class A Common Stock (BLLN)?
The market capitalisation of BillionToOne, Inc. Class A Common Stock is $6.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BillionToOne, Inc. Class A Common Stock (BLLN)?
The price-to-sales ratio of BillionToOne, Inc. Class A Common Stock is 4.45 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BillionToOne, Inc. Class A Common Stock (BLLN)?
Earnings per share at BillionToOne, Inc. Class A Common Stock are $0.5400 (price ÷ EPS = P/E 182.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BillionToOne, Inc. Class A Common Stock (BLLN)?
The net margin of BillionToOne, Inc. Class A Common Stock is 2.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BillionToOne, Inc. Class A Common Stock (BLLN)?
The return on equity (ROE) of BillionToOne, Inc. Class A Common Stock is 8.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BillionToOne, Inc. Class A Common Stock (BLLN)?
On an EBIT basis the return on assets of BillionToOne, Inc. Class A Common Stock is −16.4% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BillionToOne, Inc. Class A Common Stock (BLLN)?
The operating margin of BillionToOne, Inc. Class A Common Stock is 16.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BillionToOne, Inc. Class A Common Stock (BLLN)?
Revenue at BillionToOne, Inc. Class A Common Stock is growing +83.8% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does BillionToOne, Inc. Class A Common Stock (BLLN) hold?
BillionToOne, Inc. Class A Common Stock holds more cash than debt, $387M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch BillionToOne, Inc. Class A Common Stock in the live analysis

One click puts BillionToOne, Inc. Class A Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.